Oramed Pharmaceuticals (ORMP) Gross Profit (2016 - 2025)

Oramed Pharmaceuticals' (ORMP) quarterly Gross Profit came in at $13000.0 in Q1 2025, down 98.09% on a QoQ basis from $681000.0 in Q3 2019.

Oramed Pharmaceuticals (ORMP) Gross Profit (2016 - 2025) Analysis & Trends

Oramed Pharmaceuticals (ORMP) has 5 years of Gross Profit data on file, last reported at $13000.0 in Q1 2025.

Quarterly Gross Profit changed N/A year-over-year to $13000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $13000.0 (changed N/A YoY) and the FY2025 annual result came in at $13000.0, changed N/A from the prior year.
Gross Profit declined to $13000.0 in Q1 2025, from $681000.0 in the prior quarter.
In the past five years, Gross Profit ranged from a high of $13000.0 in Q1 2025 to a low of $13000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Oramed Pharmaceuticals	197.61 Mn	197.61 Mn	-

Download Data